Recce Pharmaceuticals Ltd. announced it completed dosing the first healthy subjects at the higher concentration of 3,000mg within a fast infusion rate of 15-minutes in a Phase I/II trial evaluating its lead anti-infective candidate, RECCE® 327 (R327). An independent safety committee recently unanimously concluded that R327 is safe and well tolerated in healthy male and female subjects at an infusion rate of 3,000mg via intravenous administration over 30 minutes. Since the previous cohort dosed, the committee approved a faster infusion rate, double that of what was previously delivered at 30 minutes, now being delivered at 3,000mg over 15 minutes.